Zagami Paola, Carey Lisa Anne
Department of Oncology and Hematology, University of Milano, Milan, Italy.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
NPJ Breast Cancer. 2022 Aug 20;8(1):95. doi: 10.1038/s41523-022-00468-0.
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10-15% of incident breast cancers and carries the worst prognosis. TNBC is overrepresented among Black and pre-menopausal women and is associated with significant psychological and treatment-related burdens, including financial toxicity. Like other breast cancers, TNBC is biologically heterogeneous, leading to diverse clinical and epidemiological behaviors, however, unlike the other clinical subtypes, in TNBC we still lack tumor-specific targeted therapy. Early TNBC outcomes have improved due to the intensification of therapies, including improvements in polychemotherapy and the addition of immunotherapy. Future efforts are needed to identify targetable aberrations for specific drug therapy, prevent immune evasion, and increase social-economic support. Given that the name TNBC illustrates its lack of specifically targeted and effective therapy, we look forward to being able to retire the name in favor of a group of targetable entities within what is now called "TNBC".
三阴性乳腺癌（TNBC）的特征是缺乏雌激素和孕激素受体表达，且不存在HER2过表达或基因扩增。它占新发乳腺癌的10%-15%，预后最差。TNBC在黑人女性和绝经前女性中更为常见，并且与包括经济毒性在内的重大心理和治疗相关负担有关。与其他乳腺癌一样，TNBC在生物学上具有异质性，导致不同的临床和流行病学行为，然而，与其他临床亚型不同的是，在TNBC中我们仍然缺乏肿瘤特异性靶向治疗。由于治疗的强化，包括多药化疗的改进和免疫治疗的加入，早期TNBC的治疗结果有所改善。未来需要努力确定可用于特定药物治疗的可靶向异常，防止免疫逃逸，并增加社会经济支持。鉴于TNBC这个名称表明其缺乏特异性靶向和有效治疗，我们期待能够摒弃这个名称，转而采用现在称为“TNBC”的一组可靶向实体。
